We adressed the gender diversity first because we were concerned about the relatively low percentage of women in the board of directors and top management. The issuer acknowledged its difficulties in increasing the gender diversity but confirm that they are diligently trying to and had made recent appointments.
Regarding the access to medecine, especially for low income patients or emerging markets, the issuer explained they have implemented specific policies, either linking drug prices to purchasing power parity or encouraging the expansion of their generic division.